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Abstract 
Introduction 
• Microscopic colitis is a significant complication risk following the  > 4-8  
week use of certain H2RAs and PPIs.  
• Clinicians seek a medication that is specific, selective, and effective for the 
treatment of GERD sparing the inflammatory SEs of the intestine.  
• Improved awareness and increased use of treatments that cause 
microscopic colitis are some of the causes of more frequent diagnosis.  
• The drugs associated with microscopic colitis are proton pump inhibitors 
(PPIs) and histamine 2 receptor-antagonists (H2RAs).  
• The recommended duration of PPI therapy for mild-moderate peptic ulcer 
disease and dyspepsia is 4-8 weeks. 
• Esophagitis , Barrett’s esophagus and Zollinger-Ellison syndrome may 
require continuous therapy when upon withdrawal relapse is likely.  
• Purpose is to investigate whether the use of PPIs and H2RAs are associated 

















Applicability to Clinical 
Practice 
Thanks . . .  
Discussion 
• Microcytic colitis causing chronic diarrhea and chronic colonic 
inflammation continues to be a statistically significant complication risk 
with extended use  (4-8 weeks) of certain H2RAs and PPIs. 
• Among the drugs associated with microscopic colitis are H2RAs; ranitidine 
(Zantac) and proton pump inhibitors, lansoprazole (Prevacid), omeprazole 
(Prilosec), and esomeprazole (Nexium). 
• Diarrhea is one of the most frequently reported adverse events during the 
long term use of PPIs. The diarrhea was most commonly loose and occurred 

















• Multiple case studies suggest a causal relationship between microscopic 
colitis and lansoprazole, omeprazole and esomeprazole treatment, due to the 
temporal association of exposure, resolution of symptoms and normalization 
of histopathology upon drug withdrawal, and the immediate recurrence of 
disease with histologic abnormalities upon drug re-exposure. 
• PPIs are therapeutically more effective than H2RAs in the treatment of 
gastroesophageal reflux disease, have a higher risk profile, increased ADRs 
and are more broadly implicated in microscopic colitis. 
• Microcytic colitis causing chronic diarrhea and chronic colonic 
inflammation continues to be a significant complication risk with the 
extended use of certain PPIs (lansoprazole (Prevacid), omeprazole (Prilosec) 
and esomeprazole (Nexium) and the H2RA (ranitidine (Zantac)).  
• PPIs have the physiological and functional potential to interfere with 
gastrointestinal physiology by virtue of altering intestinal pH. 
• PPIs can also interact with mechanisms and sites of action, other than that of 
gastric H+/K+ ATPase. Colonic epithelial cells also express proton pumps, 
which are involved in maintaining local electrolyte balance.  
• Several bacteria including Heliobacter pylori and Strep pneumoniae, as well 
as fungi such as Candida albicans contain H+/K+ plus ATPase in their 
plasma membranes, which are highly similar to human plasma membranes.  
• PPIs can influence a wide variety of microbial growth, including bacteria 






• In patients with GERD receiving treatment, is there a statistical difference in 
efficacy of treatment/incidence of colitis when using H2RAs or PPIs?  






• PPIs reduce acid secretion by inhibiting the hydrochloric acid (proton) secreting pump 
(H+/ K+ ATPase) in the stomach and are anti- secretory agents. 
• PPIs enter the parietal cell, bind to the proton pump, resulting in an irreversible pump 
inactivation reducing the amount of H+ that is pumped into the  stomach lumen. The 
binding is irreversible, the effects of PPIs persist until new pumps are synthesized. 
• Concerns of small and large bowel dysbiosis , microcytic, collagenous and lymphocytic 
colitis secondary to long term PPI use ( >4-8 weeks)  are raised. 
• Diarrhea was reported in clinical trials and observational data of lansoprazole users. 
• Lansoprazole is a highly effective PPI, has been well tolerated with minimal serious 
adverse events. Diarrhea is reported in approximately 3% to 8% of study patients. 
• In collagenous colitis and lymphocytic colitis related to lansoprazole, with both clinical 
(cessation of diarrhea) and histological improvement upon cessation of this medication. 
• The most potent medications that suppress gastric acid are PPIs. They have been 
associated with dysbiosis or microbial colonization of the normally sterile upper 
gastrointestinal tract (stomach, duodenum, jejunum and ileum), with altered 






















• B12 deficiency and the use of H2RAs or PPIs for twelve months or more.  
• The use of both PPI and clopidigrel was associated with an increased risk of death or 
rehospitalization, revascularization surgery for ACS compared with that of clopidigrel 
alone without PPI.  
• Prolonged gastric acid inhibitor -induced hypochlorhydria has been correlated as a risk 
factor for severe gastrointestinal infections.  
• The causative role of lansoprazole suggest that lansoprazole related lymphocytic colitis 




• H2RAs and PPIs are widely prescribed worldwide by physicians and can 
be purchased over-the-counter by patients.  
• In 2010, 53.4 million US prescriptions for the generic antacid medication 
Prilosec (omeprazole) not including OTC sales.  
• PPIs interfere with gastrointestinal physiology by virtue of altering 
intestinal pH.  
• Hydrochloric acid is required for the breakdown and digestion of food. 
Although considered safe, long-term use has raised safety concerns.  
• Potential adverse drug reactions include Clostridium difficile infection, 
dysbiosis, changes in autoimmunity,  bone fractures, respiratory infections, 
B12, and iron malabsorption, malabsorption syndromes, watery diarrhea, 
enteric infections, small bowel bacterial overgrowth, inflammatory bowel 
disease, such as microscopic colitis, hypergastrinemia, including rebound 
secretion of hydrochloric acid and carcinoid tumors. 
• Successful GERD management includes lifestyle and behavior  
modification as first line, prior to  adding H2RAs or PPIs. 
• In high-risk populations, such as the elderly, acid reducing medications are 
short-term solutions (2-8 weeks).  
• Patient education  in avoiding  GERD triggers can decrease the frequency 
and incidence of GERD, esophagitis, peptic ulcer disease and dyspepsia.  
The author expresses sincere appreciation to Susan Kuntz, PhD who served as 
faculty advisor and mentor for this project and most notably her outstanding 
commitment to graduate students, for the formatting of this paper; the 
dedication and patience of my wife and children, all the other faculty in the 
Physician Assistant Studies Department at the School of Medicine, University 
of North Dakota.  
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